{
    "organizations": [],
    "uuid": "0dfe312a74ebb2e4152c7bef3fd7aa37b04c6f23",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-3sbio-says-unit-and-toray-sign-exc/brief-3sbio-says-unit-and-toray-sign-exclusive-licensing-agreement-on-antipuritic-agent-trk-820-idUSFWN1PA03U",
    "ord_in_thread": 0,
    "title": "BRIEF-3Sbio Says Unit And Toray Sign Exclusive Licensing Agreement On Antipuritic Agent, TRK-820​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 15 (Reuters) - 3Sbio Inc:\n* UNIT AND TORAY ENTER EXCLUSIVE LICENSING AGREEMENT ON CERTAIN ORAL DISINTEGRATION TABLET FORMULATION OF ANTIPRURITIC DRUG TRK-820​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-15T17:06:00.000+02:00",
    "crawled": "2018-01-16T13:26:11.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "3sbio",
        "inc",
        "unit",
        "toray",
        "enter",
        "exclusive",
        "licensing",
        "agreement",
        "certain",
        "oral",
        "disintegration",
        "tablet",
        "formulation",
        "antipruritic",
        "drug",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}